BMY Q3 2020 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q3 2020 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$10.5B+75.5% YoY

Gross Profit

$5.6B52.8% margin

Operating Income

$1.4B13.0% margin

Net Income

$1.9B17.8% margin

EPS (Diluted)

$0.82

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

$2.3B

Free Cash Flow

$2.1B

Stock-Based Comp.

$185M

Balance Sheet

Total Assets

$125.5B

Total Liabilities

$75.3B

Stockholders' Equity

$50.2B

Cash & Equivalents

$19.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10.5B	$6.0B	+75.5%
Gross Profit	$5.6B	$4.2B	+31.8%
Operating Income	$1.4B	$1.8B	-24.2%
Net Income	$1.9B	$1.4B	+38.4%

Revenue Segments

Revlimid

$3.0B29%

Eliquis

$2.1B20%

Opdivo

$1.8B17%

Orencia

$826M8%

Pomalyst/Imnovid

$777M7%

Sprycel

$544M5%

Yervoy

$446M4%

Abraxane

$342M3%

Mature Products And All Other

$287M3%

Baraclude

$100M1%

Empliciti

$96M1%

Reblozyl

$96M1%

Zeposia

$2M0%

Geographic Segments

UNITED STATES

$6.5B62%

Europe

$2.5B23%

Rest Of World

$1.4B13%

Other Region

$184M2%